2023-02-08 2024-02-28 false Capium Accounts Production 1.1 14650479 bus:AbridgedAccounts 2023-02-08 2024-02-28 14650479 bus:FRS102 2023-02-08 2024-02-28 14650479 bus:AuditExemptWithAccountantsReport 2023-02-08 2024-02-28 14650479 bus:SmallCompaniesRegimeForAccounts 2023-02-08 2024-02-28 14650479 bus:PrivateLimitedCompanyLtd 2023-02-08 2024-02-28 14650479 2023-02-08 2024-02-28 14650479 2024-02-28 14650479 bus:RegisteredOffice 2023-02-08 2024-02-28 14650479 core:WithinOneYear 2024-02-28 14650479 core:AfterOneYear 2024-02-28 14650479 bus:Director1 2023-02-08 2024-02-28 14650479 bus:Director1 2024-02-28 14650479 2022-02-08 14650479 bus:CompanySecretary1 2023-02-08 2024-02-28 14650479 bus:LeadAgentIfApplicable 2023-02-08 2024-02-28 14650479 2023-02-07 14650479 core:CostValuation core:Non-currentFinancialInstruments 2024-02-28 14650479 core:CostValuation core:Non-currentFinancialInstruments 2023-02-07 14650479 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-02-28 14650479 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-02-28 14650479 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-02-28 14650479 core:Non-currentFinancialInstruments 2024-02-28 14650479 core:Non-currentFinancialInstruments 2023-02-07 14650479 core:ShareCapital 2024-02-28 14650479 core:RetainedEarningsAccumulatedLosses 2024-02-28 14650479 dpl:Item1 2023-02-08 14650479 dpl:Item1 2024-02-28 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 14650479
England and Wales

 

 

 

PHARMAFFINITY LTD


Abridged Accounts
 


Period of accounts

Start date: 08 February 2023

End date: 28 February 2024
Chartered Accountants' report to the board of directors on the preparation of the unaudited statutory accounts of Pharmaffinity Ltd for the period ended 28 February 2024

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Pharmaffinity Ltd for the period ended 28 February 2024 which comprise of the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales, we are subject to its ethical and other professional requirements which are detailed at www.icaew.com/en/members/regulations-standards-and-guidance This report is made solely to the Board of Directors of Pharmaffinity Ltd, as a body, in accordance with the terms of our engagement letter.

Our work has been undertaken solely to prepare for your approval the accounts of Pharmaffinity Ltd and state those matters that we have agreed to state to the Board of Directors of Pharmaffinity Ltd, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than company_name] and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Pharmaffinity Ltd has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Pharmaffinity Ltd. You consider that Pharmaffinity Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Pharmaffinity Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts for the period ended 28 February 2024. 







....................................................
Chawton Hector
2 Maules Gardens
Bristol
Avon
BS34 8AN

27 March 2024
1
 
 
Notes
 
2024
£
Current assets    
Debtors 787 
Cash at bank and in hand 1,265 
2,052 
Creditors: amount falling due within one year (1,167)
Net current assets 885 
 
Total assets less current liabilities 885 
Net assets 885 
 

Capital and reserves
   
Called up share capital 1 
Profit and loss account 884 
Shareholder's funds 885 
 


For the period ended 28 February 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006 the income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved by the director on 27 March 2024 and were signed by:


-------------------------------
Gurpavan Bariah
Director
2
General Information
Pharmaffinity Ltd is a private company, limited by shares, registered in England and Wales, registration number 14650479, registration address 31 Roeburn Crescent, Emerson Valley, Milton Keynes, MK4 2DG.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by Section 1A of the standard)
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
2.

Average number of employees

Average number of employees during the period was 1.
3